• BIVDA members area

Members' Press Releases

Multiplicom receives €1.9M grant to develop innovative liquid biopsy based cancer tests

Multiplicom, Molecular Diagnositcs

Belgium, May 2016 - Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients.

“We are determined to continue enabling personalized medicine and in this way improve the quality of life of cancer patients. This grant and the support of the Flemish Government will help us to achieve this goal,” explains Dirk Pollet, CEO Multiplicom. “The objective of our funded project is to develop innovative and advanced non-invasive genetic tests that allow the selection of the best available treatment.”

Jurgen Del Favero, CTO at Multiplicom continues: “The development of advanced tools and tests will greatly improve the management of cancer patients. It will enable oncologists to more precisely determine specific treatments per patient, monitor treatment outcomes and detect therapy resistance in a cost and time efficient manner.”

For this granted project, Multiplicom will collaborate with the VIB Laboratory of Translational Genetics, Vesalius Research Centre, KULeuven; Division of Gynaecologic Oncology, University Hospital Leuven and Antwerp University Hospital.

Flanders Innovation & Entrepreneurship stimulates growth and innovation by granting financial support to promising companies. Flanders Innovation & Entrepreneurship (Agentschap Innoveren & Ondernemen) is a government agency, charged with implementing the economic, innovation and enterprise policy in Flanders.

About Multiplicom N.V.

Multiplicom N.V. develops, manufactures and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicine. Founded in 2011 as a spin-off from the University of Antwerp and VIB, Multiplicom achieved end of 2012 its first CE-IVD-certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition. It was the first company in Europe achieving a BRCA CE-IVD certification and it continues to develop and market quality controlled MPS-based assays. Therefore, it enables clinical laboratories to diagnose patients with a genetic disease or predisposition, steer cancer therapy, and identify congenital defects early in pregnancy. The Multiplicom N.V. site, located in Belgium, operates a Quality Management System to design, develop, manufacture and distribute CE-IVD products according to ISO 13485:2012. For further information please visitwww.multiplicom.com.

Contact

Dirk Pollet
CEO, Multiplicom N.V.
+32 3 289 14 00
dirk.pollet@multiplicom.com

Comments are closed for this post, but if you have spotted an error or have additional info that you think should be in this post, feel free to contact us.

Archive